Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now includes a government-funding lapse notice and a new v3.2.0 update, replacing the old v3.1.0 tag.SummaryDifference4%
- Check20 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, representing a minor UI change.SummaryDifference0.2%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check48 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location related to stomach cancer and its associated neoplasms, while several previous terms and resources have been removed.SummaryDifference3%
- Check63 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.